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Effects of phosphodiesterase 3A
modulation on murine cerebral
microhemorrhages
Rachita K. Sumbria1,2, Vitaly Vasilevko3, Mher Mahoney Grigoryan2, Annlia Paganini-Hill2, Ronald Kim4,
David H. Cribbs3 and Mark J. Fisher2,4,5,6*

Abstract
Background: Cerebral microbleeds (CMB) are MRI-demonstrable cerebral microhemorrhages (CMH) which commonly
coexist with ischemic stroke. This creates a challenging therapeutic milieu, and a strategy that simultaneously protects
the vessel wall and provides anti-thrombotic activity is an attractive potential approach. Phosphodiesterase 3A (PDE3A)
inhibition is known to provide cerebral vessel wall protection combined with anti-thrombotic effects. As an initial step
in the development of a therapy that simultaneously treats CMB and ischemic stroke, we hypothesized that inhibition
of the PDE3A pathway is protective against CMH development.
Methods: The effect of PDE3A pathway inhibition was studied in the inflammation-induced and cerebral amyloid
angiopathy (CAA)-associated mouse models of CMH. The PDE3A pathway was modulated using two approaches:
genetic deletion of PDE3A and pharmacological inhibition of PDE3A by cilostazol. The effects of PDE3A pathway
modulation on H&E- and Prussian blue (PB)-positive CMH development, BBB function (IgG, claudin-5, and fibrinogen),
and neuroinflammation (ICAM-1, Iba-1, and GFAP) were investigated.
Results: Robust development of CMH in the inflammation-induced and CAA-associated spontaneous mouse models
was observed. Inflammation-induced CMH were associated with markers of BBB dysfunction and inflammation, and
CAA-associated spontaneous CMH were associated primarily with markers of neuroinflammation. Genetic deletion
of the PDE3A gene did not alter BBB function, microglial activation, or CMH development, but significantly reduced
endothelial and astrocyte activation in the inflammation-induced CMH mouse model. In the CAA-associated
CMH mouse model, PDE3A modulation via pharmacological inhibition by cilostazol did not alter BBB function,
neuroinflammation, or CMH development.
Conclusions: Modulation of the PDE3A pathway, either by genetic deletion or pharmacological inhibition, does
not alter CMH development in an inflammation-induced or in a CAA-associated mouse model of CMH. The role
of microglial activation and BBB injury in CMH development warrants further investigation.
Keywords: Phosphodiesterase 3A, Cerebral microhemorrhage, Cerebral microbleeds, Cilostazol, Cerebral amyloid
angiopathy
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Background
Cerebral microbleeds (CMB) represent perivascular depositions of blood degradation products in the brain and
are a common MRI finding in cerebrovascular disease,
especially stroke and cerebral amyloid angiopathy (CAA)
[1]. The prevalence of CMB ranges between 18 and 68%
in patients with ischemic stroke, and presence of CMB
is associated with an increased risk for development of
intracerebral hemorrhage (ICH) [2]. Routine ischemic
stroke prevention strategies require anti-thrombotic
agents (platelet medications and anti-coagulants),
which may increase the risk for hemorrhage in patients
with CMB [2, 3]. Presence of CMB thus indicates a
hemorrhage-prone state of the cerebral blood vessels,
which may be exacerbated with anti-thrombotic agents.
Coexisting ischemic and hemorrhagic processes (“mixed
cerebrovascular disease”) thus pose a challenge to the
stroke neurologist. A therapeutic strategy that simultaneously protects the vessel wall and has anti-thrombotic
activity is therefore an attractive potential approach for
mixed cerebrovascular disease.
Phosphodiesterases (PDEs) are enzymes that catalyze
the hydrolysis of cyclic nucleotides (cyclic adenosine 3′5′-monophosphate (cAMP) and cyclic guanosine 3′-5′monophosphate (cGMP)) [4, 5]. Platelets possess several
PDEs (PDE2, PDE3, PDE5) that modulate the level of
cAMP and cGMP that are critical for platelet function
[6]. PDE inhibitors interfere with platelet activation
pathways by inhibiting the degradation of and thereby
increasing the intracellular levels of cAMP and cGMP.
Among the various PDEs, PDE3 has a high affinity for
both cAMP and cGMP with a preference for cAMP, and
the primary PDE3 isoform that regulates platelet function is PDE3A [7]. The PDE3A inhibitor cilostazol has
been shown to be clinically effective for secondary prevention of ischemic stroke [8, 9]. In both in vitro and in
vivo experiments, PDE3A inhibition appears to provide
blood vessel wall protection by enhancing blood–brain
barrier (BBB) properties [10–12] and reducing
hemorrhagic injury [12–15]. These observations provide
a strong rationale for utilizing PDE3A inhibition as therapy for brain microhemorrhagic disorders.
Given the above rationale, the aim of the current study
was to examine the effect of PDE3A pathway inhibition
on development of cerebral microhemorrhages (CMH),
the pathological substrate of CMB. We studied CMH
development in two well-characterized mouse models:
the inflammation-induced mouse model of CMH [16] and
an amyloid precursor protein transgenic (APP/Tg2576)
mouse model that develops CAA with spontaneous CMH
[17]. The overall hypothesis of the current study was that
the inhibition of the PDE3A pathway is protective against
inflammation-induced and CAA-associated CMH. To test
this hypothesis, two approaches for PDE3A pathway
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modulation were used: genetic deletion of PDE3A and
pharmacological inhibition of PDE3A by cilostazol. The
effects of PDE3A pathway modulation on CMH development, BBB function, and neuroinflammation were therefore investigated.

Methods
Animals and treatment

All animal procedures followed the “Principles of Laboratory Animal Care” (NIH Publication No. 85-23), were approved by the University of California, Irvine, Institutional
Animal Care and Use Committee, and followed the ARRIVE Guidelines for animal experiment reporting. To
study the effects of PDE3A inhibition on CMH development, two approaches—genetic deletion and pharmacological inhibition of the PDE3A pathway—and two mouse
models—the inflammation-induced mouse model of
CMH and an amyloid precursor protein transgenic
(APP/Tg2576) mouse model that develops CAA and
spontaneous CMH—were used.
Genetic deletion of PDE3A and CMH development

PDE3A knockout (KO) mice were used in the inflammation-induced mouse model of CMH. Heterozygous
PDE3A+/− KO breeding pairs (generously provided by
Dr. Vincent Manganiello [7, 18]) were bred in-house to
maintain a colony of homozygous PDE3A−/− KO and
wild-type (WT) littermate controls. All mice used in the
study were 16–18 months, and the average weight of the
WT and PDE3A−/− KO mice was 44 ± 1.9 and 41 ± 1.5 g,
respectively.
Lipopolysaccharide (LPS) derived from the gram-negative
bacterium Salmonella typhimurium (Sigma-Aldrich, St.
Louis, MO) was used to induce CMH development, as described previously [16]. Briefly, PDE3A−/− KO mice (n = 14)
and WT littermate controls (n = 16) were given LPS
(3 mg/kg) intraperitoneally (i.p.) at 0, 6, and 24 h. Control
PDE3A−/− KO mice (n = 6) and control WT littermates
(n = 4) received an equal volume of sterile saline i.p.
(Teknova, Hollister, CA). Mice fed and drank ad lib and
received 1 mL sterile saline subcutaneously (s.q.) on an asneeded basis to prevent dehydration. Mice were monitored
for 48 h, after which they were sacrificed (Fig. 1a). Mice that
died prematurely were excluded from histochemical and
biochemical analysis, but were used for survival analysis.
Pharmacological inhibition of PDE3A and CMH
development

The effect of pharmacological inhibition of PDE3A by
cilostazol, a selective PDE3A inhibitor [19], on CMH
development was studied in both the inflammationinduced and CAA-associated APP/Tg2576 (Tg) mouse
models. To determine the achievable plasma cilostazol
concentration, 4-month-old Tg mice and WT littermates
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Fig. 1 Experimental designs used in the current study. Workflow and treatment groups used to determine the effect of genetic deletion of
PDE3A on inflammation-induced CMH development (a), pharmacological inhibition of PDE3A with cilostazol on CAA-associated spontaneous
CMH development (b), and pharmacological inhibition of PDE3A with cilostazol on inflammation-induced CMH development (c)

were fed with mouse chow formulated with 0.03, 0.3, or
3% of cilostazol (Harlan, Madison, WI) (six WT and six
Tg mice in each group), for 2 weeks. Plasma was collected before introduction of the cilostazol diet (T0)
and after 2 weeks on the diet (T1). Cilostazol plasma
levels were measured on HPLC by Sumika Analysis &
Evaluation Service (Shanghai) Ltd.

To study the effect of cilostazol on CAA-associated
CMH, 22-month-old Tg mice and WT littermates were
housed under a 12-h light–dark cycle with free access to
chow and water. Mice were divided into four groups: Tg
mice fed regular chow (Tg; n = 6); Tg mice fed 0.3%
cilostazol diet formulated in regular chow (Tg-CIL; n = 8);
WT mice fed regular chow (WT; n = 8); and WT mice fed
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0.3% cilostazol formulated in regular chow (WT-CIL;
n = 7), for 10 weeks (Fig. 1b). Mice that died prematurely during the course of the 10 weeks were
excluded from histochemical and biochemical analysis,
but were used for survival analysis.
Nine weeks after initiation of the cilostazol or regular
diet regimen, LPS derived from the gram-negative bacterium S. typhimurium was administered (1 mg/kg dose
of i.p. at 0, 6, and 24 h) to a separate series of WT mice
fed regular chow (WT-LPS; n = 10) and WT mice fed
0.3% cilostazol formulated in regular chow (WT-CILLPS; n = 8) to study the effect of pharmacological inhibition of the PDE3A pathway on inflammation-induced
CMH development. WT mice fed regular chow and
treated with an equal volume of PBS (i.p. at 0, 6, and
24 h) served as control mice (WT-PBS; n = 8). Mice were
kept under standard vivarium conditions for 7 days after
the first LPS or PBS injection and observed twice daily
(Fig. 1c). Mice that died prematurely during the course
of the 7 days were excluded from histochemical and biochemical analysis, but were used for survival analysis.
Brain preparation

Forty-eight hours after the first LPS or saline injection
(for genetic manipulation studies) or 10 weeks after initiation of cilostazol or regular diet treatment (for pharmacological inhibition studies), animals were anesthetized
with a lethal dose of Nembutal (150 mg/kg, i.p.), cardiac
perfusions were performed using ice-cold PBS for 5 min
to flush the cerebral vasculature, and the brains were
harvested immediately. The left cerebral hemispheres
were flash-frozen using dry ice and stored at −80 °C for
biochemical analyses. The right hemispheres were fixed
in 5 mL of 4% paraformaldehyde (BM-154, Boston BioProducts, Ashland, MA) at 4 °C for 72 h for histological analyses.
Cerebral microhemorrhage detection

Fixed mouse hemi-brains were examined for grossly
visible surface CMH using a ×10 magnifying glass. Surface microhemorrhages were quantified and photographed using Canon PC2054 20 megapixel (Canon,
Tokyo, Japan). Fixed brains were placed in an agarose
mold and sectioned into 40-μm coronal sections with a
vibratome (Technical Products International, Inc., St.
Louis, MO). Every 4th, 5th, 6th, and 7th section was
collected, and approximately 30 sections were analyzed
per mouse brain.
The effect of PDE3A KO (genetic manipulation of the
PDE3A pathway) on acute CMH development was
assessed by examining the formation of hematoxylin and
eosin (H&E)-positive CMH in a 2-day study, as described previously [20]. Prussian blue (PB) staining to
detect CMH was not used for the PDE3A KO acute
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study based on previous studies from our lab [20]. For
H&E staining, every 6th section (approximately 30 sections per mouse brain) was stained with H&E by the research service core at UCI Medical Center’s Department
of Pathology and Laboratory Medicine. CMH were identified as a collection of red blood cells (RBC) that appear
red-orange under H&E staining using a light microscope
with a ×20 objective by an observer blinded to the experimental groups. All brain sections were examined,
and all identified CMH were photographed using an
Olympus BX40 microscope and CC-12 Soft-Imaging
System with Olympus Microsuite™-B3SV software. Digitized images were analyzed using NIH ImageJ version
1.46r to determine CMH number, size (μm2), and positive area (sum of the area occupied by all the individual
H&E-positive CMH expressed as a percentage of the
total area analyzed) per mouse by an observer blinded to
the experimental groups. To determine the total area analyzed, H&E-stained slides were scanned using the
Canon MP250 scanner (Canon, Tokyo, Japan) under 600
dots per inch (DPI). The total area of each brain section
was quantified using NIH ImageJ software and added
to determine the total tissue area that was analyzed
per mouse. The total CMH positive area was then normalized to the total tissue area for each mouse and
expressed as a percentage of the total area analyzed, as
mentioned above.
To study the effect of the PDE3A inhibitor cilostazol
on CAA-associated CMH development, the PB method
for hemosiderin (a marker of subacute CMH) was used
[17, 20]. Briefly, three coronal sections per brain with
coordinates −1.2, −2.2, and −3.2 mm posterior to the
bregma selected according to The Mouse Brain in
Stereotaxic Coordinates were stained with PB and counterstained with nuclear fast red [21]. All brain sections
were examined, images of microscopic hemorrhages were
taken using Olympus BX-UCB microscope with a ×20 objective, and CMH were analyzed using NIH ImageJ software by an investigator blinded to the experimental
groups. Eclipse tool was used as a convex hull to encircle
the CMH to determine the average size and total positive
area of the PB-positive lesion in square micrometers based
on the incorporated scale bar. For the total PB-positive
area, individual PB-positive lesions for all the three brain
sections were summed. The number, average size, and
total area of PB-positive CMH per section were reported
as described previously [17].
TNF-α and β-TG ELISA

In the genetic manipulation studies, blood samples were
obtained before and 26 and 48 h after LPS or saline injection via the retro-orbital sinus using heparinized capillary tubes (Fisher Scientific, Hampton, NH). For this,
mice were briefly anesthetized using 3% isoflurane.
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Blood samples were collected on ice and centrifuged at
8000 × g for 15 min at 4 °C. For TNF-α (a marker of systemic inflammation) ELISA, supernatant was collected
and assayed using a TNF-α ELISA kit (Life Technologies,
Carlsbad, CA) as per the manufacturer’s protocol. For βthromboglobulin (β-TG; a marker of platelet activation)
ELISA, blood was collected in 1-mL Eppendorf tubes
prefilled with a plasma collection solution (21% by volume of collected blood) to prevent in vitro platelet activation and assayed using a β-TG ELISA kit (US
Biological, 023697, Salem, MA) as per the manufacturer’s instructions. The plasma collection solution for
β-TG comprised acid–citrate–dextrose (ACD) National
Institutes of Health formula A (Sigma-Aldrich, St.
Louis, MO), aspirin (Sigma-Aldrich, St. Louis, MO),
and prostaglandin E1 (Sigma-Aldrich, St. Louis, MO) at
a 100:8:1 ratio, respectively [22].
Immunohistochemistry

Immunohistochemistry was performed for ICAM-1 (inflammation-inducible protein intercellular adhesion
molecule-1; a marker of endothelial cell activation), IgG
(a marker of BBB damage), Iba-1 (ionized calciumbinding adaptor molecule 1; a marker of microglia/macrophages), and GFAP (glial fibrillary acidic protein; a
marker of astrocytes). Immunohistochemical analyses
[16] were performed using one coronal 40-μm section
per mouse approximately −2 to −2.4 mm posterior to
the bregma, and identical coordinate sections per staining from the analyzed groups were incubated in 0.5%
hydrogen peroxide in 0.1 M PBS (pH 7.4) containing
0.3% Triton X-100 (PBST) for 30 min at room
temperature to block endogenous peroxidase activity.
After washing with PBST, sections were incubated for
30 min with PBST containing 2% bovine serum albumin
(BSA) to block non-specific protein binding. Sections
were then incubated overnight at 4 °C with a rabbit antimouse IgG antibody (1:200 dilution; Jackson ImmunoResearch, West Grove, PA), rabbit monoclonal antibody
against ICAM-1 (1:500 dilution; Abcam, Cambridge,
MA), rabbit antibody against Iba-1 (1:200 dilution;
Wako Chemicals USA, Richmond, VA), or rabbit antibody against GFAP (1:2000 dilution; Abcam, Cambridge,
MA). After washing with PBST, sections were incubated
at room temperature for 1 h with biotinylated antirabbit IgG (1:500 dilution; Jackson ImmunoResearch,
West Grove, PA), followed by 1 h incubation at room
temperature with ABC complex according to manufacturer instructions (Vector Laboratories, Burlingame,
CA). Sections were developed with 3,3′-diaminobenzidine (DAB) (Vector Laboratories, Burlingame, CA).
Sixteen images per brain section from the frontal cortex,
hippocampus, and thalamus areas were acquired randomly at ×20 magnification, and the total positive
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immunoreactive area (expressed as % of the total area
analyzed) was quantified using NIH ImageJ software by
an observer blinded to the experimental groups.
Claudin-5 and fibrinogen western blot

Frozen left cerebral hemispheres were pulverized, the
powder was homogenized in T-PER buffer (Thermo
Fisher Scientific, Waltham, MA) with protease inhibitor
cocktail (Roche Applied Science, Indianapolis, IN), and
soluble fraction was collected after 100,000g centrifugation for 1 h at 4 °C. Protein concentrations for western
blot analysis were determined using the Bradford protein
assay, and approximately 50 μg of protein was resolved
on SDS-PAGE 4–12% gel (Invitrogen, Carlsbad, CA).
Primary antibodies for claudin-5 (tight junction protein)
(Abcam, Cambridge, MA) and fibrinogen (a marker of
BBB permeability) (US Biological, Salem, MA) were used
at 1:2000 dilution followed by HRP-conjugated donkey
anti-rabbit secondary antibody (Jackson Immuno Research, West Grove, PA). NIH ImageJ software was used
to quantify western blot band intensities. Control protein
GAPDH (Santa Cruz Biotechnology, Dallas, TX) was
used to normalize band intensity measurements.
Statistical analysis

Data were represented as mean ± SEM, and all statistical
analyses were performed using GraphPad Prism 5
(GraphPad Software Inc., La Jolla, CA). To compare more
than two groups, one-way ANOVA with Bonferroni’s post
hoc test was used for normal data and the Kruskal-Wallis
test with Dunn’s post hoc test for non-normal data.
The Student t test was used to compare two groups
with normally distributed data. Survival curves were
analyzed using the Log-rank test. One-sample t test
was used to compare group means with a hypothesized mean = 0 when the values in the control group
were zero (e.g., surface microhemorrhages and TNF-α
levels in the control mice). A p value of <0.05 was
considered statistically significant.

Results
Survival

While studying the effect of genetic deletion of PDE3A
on CMH development, all the control mice (control
PDE3A−/− KO (n = 6) and control WT littermates (n = 4))
and LPS-treated WT mice (n = 16) survived the duration
of the study. The LPS-treated PDE3A−/− KO mice had a
significantly lower (p < 0.01) survival (9 of 14) compared
with the LPS-treated WT mice (Fig. 2a).
While studying the effect of pharmacological inhibition of PDE3A with cilostazol on CAA-associated CMH
development, the survival of mice was as follows: 8/8 in
the WT group, 6/7 in the WT-CIL group, 5/6 in the Tg
group, and 8/8 in the Tg-CIL group (Fig. 2b). No
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Fig. 2 Survival analysis for the different experimental groups.
Significant decrease in survival of PDE3A KO mice treated with LPS
compared with the WT, PDE3A KO, and LPS-treated WT mice while
studying the effect of genetic deletion of PDE3A on inflammationinduced CMH development (a). No difference in the survival
between any experiment groups while studying the effect of
pharmacological inhibition of PDE3A with cilostazol on CAA-associated
CMH development (b). LPS treatment caused a significant reduction
in survival in the WT and WT-CIL treated mice compared with PBStreated WT mice while studying the effect of pharmacological
inhibition of PDE3A with cilostazol on inflammation-induced CMH
development (c). Statistical test: Log-rank test for survival analysis.
#p < 0.05 compared with WT, PDE3A KO, and LPS-treated WT,
*p < 0.05 compared with WT-PBS

significant difference in the survival was observed between
any experiment groups. While studying the effect of
pharmacological inhibition of PDE3A with cilostazol on
inflammation-induced CMH development, the survival of
mice was as follows: 8/8 in the WT-PBS group, 5/10 in
the WT-LPS group, and 5/8 in the WT-CIL-LPS group
(Fig. 2c). LPS treatment caused a significant reduction
(p < 0.05) in survival in the WT and WT-CIL treated
mice compared with the PBS-treated WT mice.
Genetic deletion of PDE3A and surface cerebral
microhemorrhages

No grossly visible CMH were visible on the brain surface
of mice treated with saline, in either WT or PDE3A−/−
KO mice. A 3 mg/kg dose of LPS at 0, 6, and 24 h induced the development of grossly visible surface microhemorrhages 48 h after the first LPS injection, in both
WT (9.5 ± 1.9 per brain; p < 0.05) and PDE3A−/− KO
(8.3 ± 2.9 per brain; p < 0.05) mice compared with saline
controls (Fig. 3a). Genetic deletion of PDE3A had no
significant effect on LPS-induced surface microhemorrhage development, and no significant difference between LPS-treated WT and LPS-treated PDE3A−/− KO
mice was observed.
Genetic deletion of PDE3A and H&E-positive acute
parenchymal cerebral microhemorrhages

Negligible H&E-positive acute parenchymal CMH were
observed in saline-treated WT (0.021 ± 0.008 per brain
section) and PDE3A−/− KO (0.06 ± 0.03 per brain section) mice. A 3 mg/kg dose of LPS at 0, 6, and 24 h significantly increased the formation of H&E-positive acute
parenchymal CMH in both the WT (0.71 ± 0.16 per
brain section) and PDE3A−/− KO (1.2 ± 0.46 per brain
section) mice compared with their respective salinetreated controls (Fig. 3b). There was a trend toward a
higher H&E-positive CMH number in the LPS-treated
PDE3A−/− KO mice compared with the LPS-treated WT
mice (p > 0.05).
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Fig. 3 Genetic deletion of PDE3A and inflammation-induced CMH development: Significant increase in grossly visible surface CMH in the LPStreated WT and LPS-treated PDE3A KO mice compared with their respective saline controls (a). Significant increase in H&E-positive parenchymal
CMH number (b), size (c), and area (d) in the LPS-treated WT and LPS-treated PDE3A KO mice compared with their respective saline controls.
Representative images of H&E-positive CMH in saline- and LPS-treated WT and PDE3A−/− KO mice (e). Data are presented as mean ± SEM.
Statistical test: one-way ANOVA with Bonferroni’s post-test or Kruskal-Wallis test with Dunn’s post-test for parenchymal CMH and one-sample
t test with a hypothesized mean = 0 for surface CMH. *p < 0.05, **p < 0.01, ***p < 0.001

LPS treatment produced H&E-positive CMH that were
significantly larger in size compared with the saline controls, in both the WT and PDE3A−/− KO mice. However,
the mean CMH size did not differ significantly between
LPS-treated WT and LPS-treated PDE3A−/− KO mice
(Fig. 3c). Similarly, the total CMH load (or the CMH
positive area) was significantly higher in the LPS-treated
WT and LPS-treated PDE3A−/− KO mice compared with
their respective saline-treated controls, but no difference
between LPS-treated WT and LPS-treated PDE3A−/−
KO mice was observed (Fig. 3d). Representative images
of H&E-positive CMH in the saline- and LPS-treated
WT and PDE3A−/− KO mice are shown in Fig. 3e.
Overall, genetic deletion of PDE3A did not significantly
alter H&E-positive inflammation-induced acute CMH
development in the current study.

and PDE3A−/− KO (131 ± 35 pg/mL) mice and the TNF-α
levels were significantly higher in the WT mice compared
with the PDE3A−/− KO mice (Fig. 4a). TNF-α levels continued to be significantly elevated at 48 h after the first
LPS injection compared with saline controls; however, no
significant difference was observed between LPS-treated
WT (61 ± 8 pg/mL) and LPS-treated PDE3A−/− KO (62 ±
11 pg/mL) mice (Fig. 4a). Serum TNF-α levels were significantly associated (Spearman r = 0.48, p < 0.05) with the
CMH load in the LPS-treated WT mice (Fig. 4b), but no
significant correlation was observed in the LPS-treated
PDE3A−/− KO mice. No significant difference was observed in the extent of platelet activation as measured by
plasma β-TG between the groups (data not shown).

Serum TNF-α and β-TG levels

The plasma cilostazol readings were negligible in mice
before the diet introduction (0.15 ± 0.15 ng/mL) and increased in the 0.03% (1175 ± 303.2 ng/mL), 0.3% (3676 ±
495.6 ng/mL), and 3% (4088 ± 670.4 ng/mL) groups. These
levels are comparable to the plasma levels of cilostazol in
humans following a 200 mg dose [23]. The mean cilostazol

TNF-α levels were close to the detection limit in the
saline-treated WT and PDE3A−/− KO mice (data not
shown). Two hours after the last LPS injection (or 26 h
after the first LPS injection), serum TNF-α levels were
significantly elevated in both the WT (265 ± 60 pg/mL)

Pharmacological inhibition of the PDE3A pathway with
cilostazol and CMH development

Sumbria et al. Journal of Neuroinflammation (2017) 14:114
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Fig. 4 Significant increase in serum TNF-α levels in LPS-treated WT mice compared with LPS-treated PDE3A KO mice, 26 h after the first LPS
injection (or 2 h after the last LPS injection) (a). No significant difference in the serum TNF-α levels between the LPS-treated WT mice compared
with the LPS-treated PDE3A KO mice, 48 h after the first LPS injection (a). No detectable TNF-α levels were observed in the saline-treated WT
and PDE3A KO mice. Significant correlation between the serum TNF-α levels of LPS-treated WT mice and number of H&E-positive CMH (N = 15).
(b). Data are presented as mean ± SEM (a) and scatter plot with Spearman correlation coefficient (b). Statistical test: Student’s t test for TNF-α
level comparison at 26 h and Spearman correlation coefficient. *p < 0.05

plasma levels were similar in the 0.3 and 3% groups and
significantly higher than in the control and 0.03% groups.
Based on this, a 0.3% cilostazol supplemented diet was
used for the pharmacological inhibition studies.
In the studies examining the effect of cilostazol on
CAA-associated spontaneous CMH development, we
found that APP/Tg2576 (Tg) mice had a significantly
higher number of spontaneously developed CAA-associated PB-positive CMH (12 ± 1.1 CMH per brain section;
p < 0.01) compared with the WT littermates (3 ± 0.6 CMH
per brain section) (Fig. 5a). Ten weeks of treatment with
cilostazol, however, did not significantly alter the number
of PB-positive CMH in both the Tg (8 ± 2 CMH per brain
section) and WT (5 ± 2 CMH per brain section) mice as
shown in Fig. 5a. Similarly, the average size and total area
of the PB-positive lesions were significantly higher in the
Tg mice compared with the WT littermates, and cilostazol
treatment did not affect the size and area in WT or Tg
mice (Fig. 5b, c). The PB-positive lesion size and total area
was 701 ± 189 and 2608 ± 970 μm2 in the WT mice and
497 ± 161 and 2086 ± 800 μm2 in the WT-CIL mice, respectively. Similarly, the PB-positive lesion size and total
area was 5040 ± 1206 and 61,971 ± 15,561 μm2 in the Tg
mice and 9918 ± 2412 and 91,594 ± 30,473 μm2 in the TgCIL mice, respectively. Representative images showing
PB-positive lesions in the WT and Tg mice with and without cilostazol treatment are shown in Fig. 5d. Overall, Tg
mice had significantly higher CAA-associated PB-positive
CMH development compared to WT mice, and 10-week
cilostazol treatment did not alter PB-positive CMH development in the WT and Tg mice.
In the studies examining the effect of cilostazol on inflammation-induced PB-positive (subacute) CMH development, we found that the PB-positive lesion number,
size, and area were significantly higher in the LPS-treated
WT mice fed regular diet compared with the PBS controls
fed regular diet (Fig. 6a–c). Cilostazol treatment did not

alter the PB-positive lesion number, size, or total area in
the LPS-treated WT mice (Fig. 6a–c). Representative images showing PB-positive lesions in the WT, WT-LPS,
and WT-LPS-CIL mice are shown in Fig. 6d. Overall,
10-week cilostazol treatment did not alter PB-positive
inflammation-induced CMH development.
Genetic and pharmacological modulation of the PDE3A
pathway, neuroinflammation, and blood–brain barrier
function

Figures 7 and 8 show the effect of PDE3A modulation
on the various markers of neuroinflammation and BBB
function in the inflammation (LPS)-induced and CAAassociated CMH mouse models.
In the inflammation-induced CMH mouse model used
for the PDE3A KO studies, LPS treatment produced a
significant increase in brain levels of ICAM-1 (a marker
of endothelial activation) (Fig. 7a), markers of neuroinflammation (Iba-1 and GFAP) (Fig. 7b, c), and BBB function (IgG, fibrinogen, and claudin-5) (Fig. 7d–f ) in the
WT and PDE3A−/− KO mice compared with salinetreated controls. With genetic deletion of PDE3A, there
was a significantly reduced ICAM-1 positive immunoreactive area in both the presence and absence of LPS.
GFAP positive immunoreactive area was significantly
lower in the LPS-treated PDE3A−/− KO mice compared
with the LPS-treated WT littermates (Fig. 7a, c). Genetic
deletion of PDE3A did not alter microglial activation
(Iba-1) or BBB function (IgG, claudin-5, and fibrinogen),
either in the presence or absence of LPS.
In the CAA-associated CMH mouse model used for
the pharmacological inhibition studies with cilostazol,
the ICAM-1 and Iba-1 positive immunoreactive areas
were significantly higher in the Tg mouse brains compared with the WT littermates, while increases in the
GFAP positive immunoreactive area in the Tg mice
reached statistical significance only in those mice treated
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Fig. 5 Pharmacological inhibition of PDE3A and CAA-associated spontaneous CMH development. Significant increase in Prussian blue (PB)positive CMH number (a), size (b), and area (c) in the Tg mice compared with the WT mice. No significant effect of PDE3A inhibition by
cilostazol on any of these CMH parameters. Representative images of PB-positive lesions (indicated by arrows) in WT and Tg mice with or
without cilostazol treatment (d). Data are presented as mean ± SEM. Statistical test: one-way ANOVA with Bonferroni’s post-test or KruskalWallis test with Dunn’s post-test. *p < 0.05, **p < 0.01

with cilostazol (Fig. 8a–c). Markers of BBB function
(brain parenchymal IgG, fibrinogen, and claudin-5) did
not differ significantly between the WT and Tg mice
(Fig. 8d–f ). Cilostazol treatment had no significant effect
on any marker of endothelial activation, neuroinflammation (except GFAP), or BBB function in either WT or Tg
mice compared with their respective regular feed controls
(Fig. 8a–f). In the inflammation-induced CMH mouse
model, cilostazol treatment did not reduce markers of
endothelial, astrocyte, or microglial activation, or injury to
BBB (data not shown).

Discussion
In the current study, we investigated the effects of
PDE3A pathway modulation in two mouse models of
CMH: the inflammation-induced mouse model and the
amyloid precursor protein transgenic mouse model that
develops CAA and spontaneous CMH. Our main finding
is that PDE3A pathway modulation, either by genetic
deletion of PDE3A or pharmacological inhibition of the
PDE3A isoform by cilostazol, did not alter CMH

development. This effect of PDE3A pathway modulation
on CMH development is consistent with no reduction in
BBB injury that was observed with both genetic deletion
of PDE3A and cilostazol treatment.
CMH is the pathological substrate of CMB and represents a hemorrhage-prone state of the brain. In the
current study, we used two models of CMH. Because
inflammation plays a central role in CMB development
[16], in our first model, LPS was used to induce the formation of CMH. Consistent with previous work, LPS
treatment resulted in robust development of acute H&Epositive CMH, and LPS-induced acute CMH formation
in this model was associated with an increase in endothelial activation (ICAM-1), markers of neuroinflammation (Iba-1 and GFAP), and BBB injury (IgG and
fibrinogen) [16]. Interestingly, LPS-induced acute H&Epositive CMH development was accompanied by an increase in claudin-5 levels. Claudin-5 is a dynamic tight
junction protein that is shown to undergo temporal
changes with BBB disruption, and studies report increased claudin-5 expression with BBB disruption [24].
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Fig. 6 Pharmacological inhibition of PDE3A and inflammation-induced CMH development. Significant increase in LPS-induced PB-positive CMH
number (a), size (b), and area (c) in the WT mice compared with PBS controls. Representative images of PB-positive lesions (indicated by arrows) in
WT controls, mice treated with LPS or with LPS and cilostazol (d). No effect of cilostazol treatment on any of these CMH parameters. Data are presented as mean ± SEM. Statistical test: one-way ANOVA with Bonferroni’s post-test or Kruskal-Wallis test with Dunn’s post-test. *p < 0.05, **p < 0.01

This may explain the elevated claudin-5 levels in mice
treated with LPS that have increased BBB permeability
as indicated by an increase in brain IgG and fibrinogen
(Fig. 7d, e). Further, LPS-induced acute CMH were associated with peripheral TNF-α levels, corroborating other
work showing a link between peripheral inflammation
and CMH development [25]. These results support the
notion that inflammation-induced injury at multiple sites
of the cerebral vasculature results in reduced BBB function, which is central to acute CMH development [26].
PDE3, also known as cGMP-inhibited PDE, comprises
two subfamilies, PDE3A and PDE3B. Both isoforms show
unique expression patterns; PDE3A is highly expressed by
the cardiovascular system, whereas PDE3B is highly
expressed in the cells involved in lipid metabolism and
glucose regulation [27]. Both isoforms are expressed in
mouse brain regions including the cortex, subcortex, and
cerebellum [28]. Inhibition of PDE3A, either by genetic
manipulation or pharmacologically, increases the levels of
cAMP, thus interfering with platelet activation pathways
[29]. PDE3A inhibition also provides anti-oxidant, antiinflammatory, and microvascular vessel wall protection

[3]. These properties of PDE3A inhibition make this approach particularly attractive for CMH treatment when
both ischemic and hemorrhagic lesions coexist [3]. PDE3A
inhibition by cilostazol has been reported to protect the
BBB via mechanisms including nitric oxide production
[30], MMP-9 modulation [15, 31], protection of tight
junction proteins [11, 32], and increase in phospho-CREB
[32]. These effects of cilostazol appear to result in reduced
hemorrhagic transformation in mouse models of ischemic
stroke [15, 31].
In the current study, genetic deletion of the PDE3A
isoform did not alter CMH development in the LPSinduced mouse model of CMH and provided no protection against BBB injury and microglial activation. PDE3A
KO mice treated with LPS had lower survival compared
with the other experimental groups, for reasons that are
unclear. Genetic deletion of PDE3A significantly reduced
LPS-induced markers of peripheral (serum TNF-α) and
brain (ICAM-1 and GFAP levels) inflammation. Reduction in LPS-induced peripheral TNF-α in the PDE3A
KO mice in the current study is consistent with previous
work showing significant reduction in LPS-induced
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Fig. 7 Effect of genetic deletion of PDE3A on neuroinflammation and BBB function in the inflammation-induced CMH mouse model. Significant
increase in ICAM-1 (a), Iba-1 (b), and GFAP (c) positive immunoreactive area in the LPS-treated WT and LPS-treated PDE3A KO mice compared
with their respective saline controls. Significant reduction in ICAM-1 in both the saline-treated PDE3A KO and LPS-treated PDE3A KO mice
compared with their respective WT controls (a). Significant reduction in GFAP positive immunoreactive area in the LPS-treated PDE3A KO
mice compared with LPS-treated WT mice (c). No effect of PDE3A deletion on Iba-1. Significant increase in brain IgG (d), fibrinogen (e), and
claudin-5 (f) in the LPS-treated WT and LPS-treated PDE3A KO mice compared with their respective saline controls. No significant difference in
any of these markers of BBB function with PDE3A deletion. Data are presented as mean ± SEM. Statistical test: one-way ANOVA with Bonferroni’s
post-test or Kruskal-Wallis test with Dunn’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

TNF-α production in vitro with PDE3A inhibition [33].
Peripheral TNF-α and brain ICAM-1 and GFAP were
significantly associated with CMH development in WT
mice [16]. However, in spite of reduction in these
markers of inflammation, we saw no reduction in LPSinduced CMH development in the PDE3A KO mice. We
also observed that the peripheral TNF-α levels were not
associated with LPS-induced CMH in the PDE3A KO
mice. These results imply that BBB injury and microglial
activation, rather than endothelial and astrocyte activation, are involved in LPS-induced CMH development, a
subject requiring further investigation.
Clinical evidence shows that the use of platelet medications increases the prevalence of CMB and ICH in patients
with ischemic stroke and CAA [3]. In CAA patients, presence of CMB predicts the risk of future ICH, and studies
show that the use of anti-thrombotic agents increases the
risk of ICH in patients with CAA [34]. A recent study in a

transgenic mouse model of CAA reported protective effects of PDE3A inhibition on degeneration of pericytes
and microvascular smooth muscle cells, as well as improvement in perivascular drainage and rescue of CAAassociated behavior deficits, when applied early and long
term [35]. The same study reported a dramatic increase in
PDE3A expression in cerebral vessels severely affected by
CAA. In our study, 22-month-old Tg2576 showed robust
development of CAA-associated spontaneous PB-positive
CMH; these subacute or chronic CMH were primarily
associated with markers of neuroinflammation rather than
active BBB dysfunction, consistent with previous work
[36]. The dose of cilostazol used in our experiment was
comparable to that used by Maki and group [35]; however,
we did not observe significant changes in CAA-associated
number, size, or area of spontaneous CMH after PDE3A
inhibition. Further, cilostazol intervention in Tg2576 mice
did not affect neuroinflammation and BBB function. The
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Fig. 8 Effect of pharmacological inhibition of PDE3A on neuroinflammation and BBB function in the CAA-associated CMH mouse model. Significant increase in ICAM-1 (a) and Iba-1 (b) positive immunoreactive area in the Tg mice compared with the WT mice. No effect of PDE3A inhibition
with cilostazol on ICAM-1 and Iba-1. Significant increase in GFAP positive immunoreactive area in the Tg mice treated with cilostazol compared
with treated WT mice (c). No significant difference in brain IgG (d), fibrinogen (e), and claudin-5 (f) between Tg and WT mice. Pharmacological inhibition of PDE3A had no effect on any of these markers of BBB function. Data are presented as mean ± SEM. Statistical test: one-way ANOVA with
Bonferroni’s post-test or Kruskal-Wallis test with Dunn’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001

lack of changes in Tg2576 mice may be due to the shorter
period of intervention (10 weeks in the current study vs 8,
14, or 17 months, reported in [35]) and the late start of
intervention (22 months old), when Tg2576 mice have
significant CAA and CAA-associated CMH. Prophylactic
intervention may be more efficient than therapeutic treatment (e.g., 10 weeks in the current study), for the modulation of CAA and CAA-associated CMH.
This is the first study to report the effects of genetic
deletion of the PDE3A isoform on neuroinflammation
and BBB injury associated with microscopic lesions such
as CMH. A limitation of our study is that we cannot rule
out the possibility that global inhibition of the PDE3A
pathway in this model caused an increase in other PDE
isoforms that are ubiquitously expressed in the brain
[37] as a compensatory mechanism to degrade cAMP
[38, 39]. Another limitation of our study is that the work
analyzed only inflammation- and CAA-induced CMH,
and did not address other causes of CMH, e.g., hypertension. Further, two different histology protocols were
used for the genetic deletion and pharmacological
inhibition studies: H&E for acute CMH detection in the
genetic deletion studies and PB for the detection of
subacute CMH in the pharmacological inhibition studies.
Finally, absence of protection against CMH development
in these models does not rule out a potential therapeutic
role for PDE3A modulation in mixed cerebrovascular

disease. Given the known anti-thrombotic effects of
PDE3A inhibition, absence of enhanced CMH development is modestly encouraging. This positive feature is mitigated by the absence of BBB protection in these studies.

Conclusions
Our study showed that modulation of the PDE3A pathway
does not alter development of CMH. These findings were
similar for mouse models using either genetic deletion
or pharmacological inhibition of the PDE3A pathway.
Neither CMH development nor BBB function was
altered with PDE3A pathway modulation in both the
inflammation-induced and CAA-associated mouse models
of CMH. The role of microglial activation and BBB injury
in CMH development warrants further investigation.
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